Navigation Links
Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial
Date:6/14/2012

AMSTERDAM, June 15, 2012 /PRNewswire/ --

"Hodgkin lymphoma has become one of the most curable malignancies in adults," was stated by Dr Andreas Engert, Professor of Hematology at the University Hospital of Cologne in Germany.   Results of the German Hodgkin Study Group (GHSG) HD 15 trial are presented at the 17th Congress of the European Hematology Association in Amsterdam.

Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear. We thus conducted a prospectively randomized clinical trial comparing the standard of care (8 x BEACOPPescalated) with two reduced-intensity chemotherapy variants. Chemotherapy was followed by positron emission tomography (PET) guided radiotherapy. In total, 2182 patients with newly diagnosed advanced stage Hodgkin lymphoma were randomized. Treatment with 6 cycles of BEACOPPescalated was not only better tolerated than 8 cycles but resulted in improved tumor control (89.3% versus 84.4%) and overall survival (94.5% versus 91.9%).  This was in part due to a lower mortality with 6 cycles as compared to 8 in terms of treatment related events (0.8% versus 2.1%) and secondary malignancies (0.7% versus 1.8%). In addition, the PET-guided radiotherapy resulted in a substantially reduced number of patients radiated in the present HD15 trial (11%). The outcome in HD15 was comparable to the prior HD9 study in which 70% had received additional radiotherapy. Thus, we suggested that 6 cycles of BEACOPPescalated is the treatment of choice for advanced stage Hodgkin lymphoma; PET performed after chemotherapy can guide the need of additional radiotherapy in this setting.  

About the EHA Annual Congress

After 16 c
'/>"/>

SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
2. Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss
3. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
4. PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduction Coil (RePneu LVRC) System
5. New Jersey Ophthamologist Now Offers Pelleve Wrinkle Reduction Treatment
6. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
7. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
8. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
9. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
10. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
11. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)...  Acsis Inc., the market leader for supply ... recently posted an article, "Future of Running ... needs for companies, extended supply chain, and explains ... no longer work today.  The article explains how ... mobile technology, machine to machine (M2M) connectivity, and ...
(Date:7/25/2014)... According to a new market ... Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and ... and Forecast (Value and Volume), 2013 - 2019", the ... in 2012 and is expected to grow at a ... USD 32.24 billion in 2019. Browse the ...
(Date:7/25/2014)... DUBLIN , July 25, 2014 ... the "Global Ophthalmic Diagnostic Devices Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 About Ophthalmic Diagnostic Device ... device used to identify a defect or deficiency in ... patients with ophthalmic disorders such as presbyopia, cataracts, glaucoma, ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... Simpson Eldredge Hersh & Jardine, P.C., one of the nations, ... lawsuit in Ohio against DePuy Orthopaedics, Inc. on behalf of ... ASR XL Acetabular System hip replacement. On August ... Johnson (NYSE: JNJ ), announced a voluntary recall ...
... Sept. 28 Cobalis Corp. (Pink Sheets: ... Call to provide investors and shareholders with further details and ... and legal issues. Shareholders and investors MUST RSVP ... October 5, 2010 at 1:15pm Pacific Time. Interested parties may ...
Cached Medicine Technology:Class Action Lawsuit Filed Against DePuy Orthopaedics, Inc. 2Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010 2
(Date:7/28/2014)... According to the Heartburn No More PDF review recently updated ... people get rid of acid reflux naturally. This ... and acid reflux. In addition, inside this book, people will ... for reflux disease. , Vkool informs in its review ... of reflux disease naturally without medications. The book also instructs ...
(Date:7/28/2014)... Shore Points Capital announced today that ... Loftware, Inc., through a recapitalization of the Company led ... lead investor in Loftware for over nine years, a ... international provider of enterprise level software solutions for supply ... investment for us, and we are proud of everything ...
(Date:7/27/2014)... 28, 2014 Hyaluronic Acid can hold ... the key to the power of Hyaluronic Serums. , ... Heshelow, founder of Sublime Beauty®. "But like collagen, it ... as ours improves skin moisture-retention and radiance." , ... to a healthy and beautiful look. Key Ingredients in ...
(Date:7/27/2014)... (HEV) transmission by blood components indicates that about 1 ... plasma. The findings, published in The Lancet , ... cells, platelets, and fresh frozen plasma) are likely to ... study retrospectively screened 225 000 individual blood donations collected ... 2013 for HEV RNA. 79 donors were found to ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The inaugural ... Latinos demonstrate their passion for protecting our environment and ... in the Southwest, will go on hiking or camping ... to show their support for permanently protecting our land, ... sharing the Latino community’s perspective on the environment like ...
Breaking Medicine News(10 mins):Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 3
... MINRAD International, Inc. (Amex: BUF ) today ... NYSE Alternext US LLC (the "Exchange") stating that a ... September 30, 2008, indicated the Company was not in ... (the "Company Guide"), namely Section 1003(a)(i), with stockholders, equity ...
... now show their drugs don,t increase chances of cardiac ... U.S. Food and Drug Administration is now asking all ... medications to undertake studies that determine whether they cause ... comes on the heels of reports that two commonly ...
... concerns about costs and increased promiscuity among teenagers appear ... human papilloma virus (HPV) to prevent life-threatening diseases, according ... Public Health. , There is an ongoing public ... to prevent against genital warts and cervical cancer, but ...
... 17 Paramedics and emergency medical technicians (EMTs) employed ... and members of Teamsters Local 375 attended the company,s ... Employee shareholders expressed their frustration with the company,s ... a new contract in the greater Buffalo, New York ...
... Growing Jacksonville Market , , ... Company, Inc. (Nasdaq: IPCM ), a leading national ... North Florida Hospitalists (NFH) and Orange Park Hospitalists (OPH) of ... greater Jacksonville market, where the IPC has already established a ...
... /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences ... services, today reported financial and operation results for the ... 2008. The Company announced a net loss of $3,568,321 ... October 31, 2008, and a net loss of $13,833,978 ...
Cached Medicine News:Health News:MINRAD Receives Notice of Failure to Satisfy a Continued Listing Rule from NYSE Alternext 2Health News:MINRAD Receives Notice of Failure to Satisfy a Continued Listing Rule from NYSE Alternext 3Health News:FDA Wants New Diabetes Drugs Tested for Heart Risks 2Health News:Fears of promiscuity pose barrier to cervical cancer vaccinations 2Health News:IPC The Hospitalist Company Acquires Two Florida Practices 2Health News:DiagnoCure announces fourth quarter 2008 and year-end results 2Health News:DiagnoCure announces fourth quarter 2008 and year-end results 3Health News:DiagnoCure announces fourth quarter 2008 and year-end results 4Health News:DiagnoCure announces fourth quarter 2008 and year-end results 5Health News:DiagnoCure announces fourth quarter 2008 and year-end results 6Health News:DiagnoCure announces fourth quarter 2008 and year-end results 7
... enable all those involved with healthcare decisions ... very latest evidence in their field of ... each year as the volume of evidence ... delivering the best single source available for ...
... concise yet complete eTextbook of standard ... disease. In addition to the Redi-Reference ... full desktop version is included at ... the electronic textbook, Redi-Reference provides periodic ...
ECG pocket is a handy reference for identifying common ECG findings....
... involved with healthcare decisions to keep up ... in their field of interest - a ... the volume of evidence increases. Cochrane Reviews ... single source available for continually updated evidence-based ...
Medicine Products: